Altana AG headquarters in Wesel, Germany. (File photo)
WESEL, GERMANY: Altana AG said the supervisory board has appointed its CFO, Martin Babilas (43) to become the CEO, on 1 Jan 2016, succeeding Dr Matthias Wolfgruber (61), who will retire.
Babilas has been the CFO of Altana AG since 2007 and in November last year, he took over additional responsibility of two of the company’s four divisions from Dr Wolfgruber.
The supervisory board also appointed Stefan Genten (46) as Altana’s new CFO as of 1 Aug. Genten worked in various management capacities for the Grunenthal pharmaceutical group for 13 years, since 2005 as a member of the corporate executive board and as the CFO. He was also in charge of operative functions, for example for the Latin American business, and as group chief operating officer for the last five years.
“The generation change in the company’s management reflects sustainable corporate development, as well as the group’s ability to change,” said Dr Klaus-Jurgen Schmieder, chairman, supervisory board, Altana AG.
“We are pleased to have attracted Stefan Genten, a proven leadership personality, to Altana. He will provide us with new impetus and we will benefit from his many years of international experience,” added Schmieder.
On 1 Jan, 2016, Martin Babilas will take over responsibility for corporate development/M&A, human resources, corporate communications and internal audit from Dr Wolfgruber. On that same date, Dr Christoph Schlunken (53) will assume responsibility for innovation management. Dr Schlunken became a third member of Altana’s management board last November.
© Worldofchemicals News